Medicament for treating a disease relating to a dysfunction of the dopaminergic synaptic transmission
AssigneesL'Air Liquide Societe Anonyme Pour L'Etude Et L'Explotation Des Procedes Georges Claude, L'Institutô de Cerveau et de la Moelle Épinière
InventorsPatrick MICHEL, Jérémie LAVAUR, Etienne HIRSCH, Marc LEMAIRE
Life of this patent
Estimating the term…
Abstract
The invention relates to a drug combination comprising gaseous xenon and at least one antagonist of the NMDA receptors in a liquid or solid form for treating a disease caused by a dysfunction of the dopaminergic synaptic transmission in a human patient. The antagonist of the NMDA receptors is preferably selected from memantine, nitromemantine, amantadine and ifenprodil. The invention allows the normal function of the dopaminergic synaptic transmission of diseased neurons with an altered function to be reestablished.
Claims12
A method for treating a disease caused by a dysfunction of dopaminergic synaptic transmission in a human patient comprising the step of administering a drug combination comprising xenon gas and at least one NMDA receptor antagonist in liquid or solid form to thereby treat the disease caused by the dysfunction of dopaminergic synaptic transmission in the human patient.
-15. (canceled)
Dependencies are inferred from the claim text.